Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from preserved travoprost to preservative-free tafluprost in ocular hypertension and open-angle glaucoma
2010-020746-98Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in ocular hypertension and open-angle glaucoma (OAG), sponsored by Santen Pharmaceutical. Primary endpoint: Change in ocular symptoms upon non-instillation at week 12. Started Sep 2010; status: completed.
02
Drugs
tafluprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2010-020746-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020746-98.